Table 1.
Cell cycle effects of BBL22
| Tissue type | % G1
|
% S phase
|
% G2/M
|
|||
|---|---|---|---|---|---|---|
| Control | BBL22 | Control | BBL22 | Control | BBL22 | |
| Breast cancer (estrogen receptor status) | ||||||
| MCF7 (+) | 68 | 46 | 12 | 10 | 10 | 40 |
| HS578t (−) | 73 | 26 | 10 | 17 | 16 | 54 |
| HBL100 (−) | 46 | 25 | 30 | 18 | 24 | 57 |
| MDA-MB-568 (−) | 47 | 28 | 17 | 20 | 29 | 50 |
| BT474 (+) | 67 | 25 | 20 | 15 | 12 | 60 |
| Prostate cancer (androgen status) | ||||||
| PC3 (independent) | 64 | 33 | 16 | 8 | 20 | 54 |
| DU145 (independent) | 71 | 34 | 15 | 20 | 9 | 32 |
| LNCaP* (dependent) | 51 | 17* | 22 | 22* | 26 | 11* |
| Other epithelial carcinomas | ||||||
| HeLa, cervical cancer | 71 | 19 | 15 | 14 | 12 | 56 |
| T98, glioblastoma | 70 | 22 | 15 | 14 | 14 | 64 |
| Hematological malignancies | ||||||
| K562, M6 (AML) | 37 | 9 | 32 | 15 | 24 | 71 |
| Nalm16, B cell (ALL) | 38 | 15 | 38 | 17 | 22 | 62 |
| Nalm6, B cell (ALL) | 53 | 31 | 31 | 17 | 15 | 43 |
| Nonmalignant breast epithelium | ||||||
| MCF10A | 37 | 33 | 25 | 25 | 36 | 38 |
| HS578BST | 39 | 40 | 21 | 18 | 38 | 41 |
| Nonmalignant prostate epithelium | ||||||
| BPH1 | 70 | 66 | 17 | 15 | 12 | 15 |
Cells in exponential log growth phase were treated with 50 μM BBL22, and cell cycle kinetics were determined by propidium iodide staining and fluorescence-activated cell sorter analysis 24 h later. These results are representative of four independent experiments. AML, acute myeloid leukemia; ALL, acute lymphocytic leukemia.
*
The sub-G1 apoptotic population comprised 49% of BBL22-treated LNCaP cells.